Sealants, glues, wound closure, anti-adhesion market segments by country

The global market for surgical sealants, glues, other wound closure and anti-adhesion products (collectively referred to as "securement "products) is, like many medtech markets, dominated by the U.S., followed by Europe.  But as one examines the performance of individual product segments in this market, it becomes clear that local markets have enough differences in their drivers to result in surprising variation from one another.

Below are illustrated the absolute size of the markets for products in securement by country and the relative contribution of revenues from each securement product type by country.  The differences stand out.

Source: Preliminary findings, Report #S180, "Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2010-2015". (Publishing October 2010)

Ablation Technologies Competing for Growing Patient Volume and Penetration of Clinical Practice, According to New MedMarket Diligence Report

Ablation technologies are a growth medtech field driven as much by physicians pursuing larger caseload as manufacturers developing innovative technologies, according to a new global report from MedMarket Diligence.

(PressMethod) – Surgical procedures focus on a wide range of clinical endpoints — the creation of a lesion to block aberrant cardiac rhythms, the destruction of cancerous tissue, the ligation of tissues with associated hemostasis, and many others — which has driven the development of an array of ablation technology types that are now competing aggressively with each other for a growing caseload of procedures. The ablation technologies with some of the most rapidly growing use rates are cryotherapy and radiofrequency ablation, followed by ultrasound, laser and, due to innovations in its implementation, radiotherapy. These are among the findings in a new medical technology report from MedMarket Diligence.

Although the applications of ablation devices include a number of aesthetic treatments, the majority of applications remain chronic disorders in areas which include cancer, cardiovascular, urology, gynecology and orthopedics. Many of these disorders are age-related, and the related device segments are driven by the aging of the global populations. Other market drivers include the Chinese government's push to modernize its healthcare facilities by building 400 hospitals per year, and developed country populations which are demanding anti-aging treatments, to which physicians are responding by purchasing equipment.

"Like the most successful medical technologies, ablation technologies have as their underlying driver for success the ability of physicians to capture greater caseload due to their ability to promote the clinical efficacy of ablation, faster healing times, fewer complications and many other benefits," says Patrick Driscoll, President of MedMarket Diligence. According to Driscoll, the top ablation technologies are growing at nearly 20% annually in manufacturer revenues. These include control systems, instrumentation and probes and other disposables used during the procedures.

The MedMarket Diligence report, "Ablation Technologies Worldwide Market, 2009-2019: Products, Technologies, Markets, Companies and Opportunities", describes alternative energy-based technologies and the nature of their effect on soft tissue, the underlying basis of the technology, the requisite systems for their use (including capital equipment, devices and disposables), and their strengths and weaknesses for specific clinical applications. The report details current and anticipated target applications and assesses the current and forecast caseload for each energy-based therapeutic considering competition from any and all alternative energy-based or other therapeutics, with current and worldwide market forecasts (2009-2019) segmented by technology type and specific clinical segment. The report provides segmentation of the worldwide ablation market by both ablation technology and region/country: Americas (USA, Canada, Mexico, Brazil), Europe (Germany, United Kingdom, France, Italy, Spain, BeNeLux), Asia/Pacific (Japan, China, India, Australia) and Rest of World. The report details the current and emerging products, technologies and markets for each energy-based therapy. The report profiles 76 key companies in this industry detailing their current products, current market position and products under development.

The report is described in detail, including table of contents and list of exhibits, at link. The report may purchased for immediate download at link.


New Technologies in Type 1 and Type 2 Diabetes Management

(See PRLog press release at link.)

As well established as the practices are for the management of types 1 and 2 diabetes, a raft of new technologies, from modest to radical, are steadily entering clinical practice and the industry, according to a new report from MedMarket Diligence.


PRLog (Press Release) – Aug 16, 2010 – The diagnosis, monitoring and management of both insulin-dependent diabetes mellitus (also known as Type 1) and non-insulin dependent diabetes mellitus (aka Type 2) is a well established practice of regulating blood glucose levels. Nonetheless, manufacturers have steadily developed new technologies that continue to improve the management of the disease by reducing burden on patients, reducing the incidence of diabetes-related complications and reducing the overall cost of the disease on healthcare systems.

“Without a doubt, the 10-year study known as Diabetes Control and Complications Trial, or DCCT, played an enormous role in validating the technologies that now routinely serve to improve the quality of life for diabetics,” says Patrick Driscoll, President of the medical technology business research firm MedMarket Diligence. “But the steady growth in diabetes prevalence worldwide, driven by increased prevalence of obesity, demographic trends and other forces, combined with persistent demand for ever less intrusive monitoring technologies and better long-term blood glucose management, creates an enormous opportunity for new technology development by diabetes product manufacturers.”

According to Driscoll, and detailed in the MedMarket Diligence report (see link), products in diabetes management represent an enormous $36 billion global market annually, encompassing insulin, blood glucose meters, lancets, test strips, insulin pumps, syringes (and other delivery devices), continuous blood glucose meters and a broad range of anti-diabetic drugs (oral hypoglycemic agents). Each of these product areas has many competitors offering and developing new products (even the area of insulin has a dozen competing companies), with a steady stream of innovations being introduced to the market and clinical practice. Moreover, aggressive research has continued to push for more advanced solutions to diabetes, including novel insulin delivery methods, pancreas transplants, islet cell transplants, stem cell approaches, antibody treatment, vaccines, novel drugs, new continuous blood glucose monitoring systems and the “holy grail” of diabetes management, a closed-loop blood glucose monitoring and insulin pump system (sometimes referred to as an “artificial pancreas”), which may be approved for marketing in the very near future.

Growth in the market for diabetes management products ranges globally from a low of about 11% annually in Europe to nearly 24% annually in Asia. Overall, the U.S. and Europe, with their advanced healthcare markets and payment systems, still represent an aggregate 68% of the global market. By product area, the segments driving the largest annual revenues are insulins and anti-diabetic drugs, comprising almost two thirds of the global sales of diabetes management products.

The MedMarket Diligence report #D510, “Products, Technologies, Markets and Opportunities in Diabetes Management Worldwide, 2009-2018,” details the worldwide incidence and prevalence by country/region of Type 1 and Type 2 diabetes and details the current and projected market for diagnostic and therapeutic products in the management of diabetes, including anti-diabetic drugs, alternative insulin types, blood glucose monitoring (including continuous monitoring devices), insulin pumps, and other established and emerging products in diabetes management. The report provides an emphasis of detail on the status of development of novel products including noninvasive monitoring, oral/inhaled/other insulin delivery. The report details the clinical and technology developments underlying this huge and evolving worldwide market, with data on products in development and on the market; market size and forecast; competitor market shares; competitor profiles; and market opportunity. Separate size, growth and competitor share data are presented for the U.S., European, Asia/Pacific and Rest of World. The report profiles active companies including detailed profile information on major competitors, brief profiles of companies with less sizeable current or potential positions in the market, plus additional profiles of companies with novel or advanced research activities in the market.

The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast. The report also assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

The report is described, with complete table of contents and list of exhibits at and may be accessed for immediate download via

Segmentation of global ablation market by geography and modality

The global market for ablation technologies is characterized, like many medtech markets, by a dominance of revenues in western economies.  There are nonetheless distinct patterns in the share of ablation by modality from one geography to the next.

Below is a simple representation of the global ablation market by major region and modality (aggregated from the detail by country in MMD report #S520):

Source: MedMarket Diligence, LLC; Report #S520, "Ablation Technologies Worldwide Market."